Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition of cannabidiol and vigabatrin and use thereof

A technology of cannabidiol and vigabatrin, applied in the treatment of West syndrome, in the field of compositions of cannabidiol and vigabatrin, can solve problems such as drowsiness, visual field defect, and blurred vision, and achieve relief Effects of side effects and good application prospects

Active Publication Date: 2020-05-08
HANYI BIO TECH CO LTD
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage is that side effects such as visual field defects, blurred vision, and drowsiness may occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of cannabidiol and vigabatrin and use thereof
  • Pharmaceutical composition of cannabidiol and vigabatrin and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 Intraperitoneal injection of NMDA to establish an animal model of West syndrome

[0041] 1. Experimental animals

[0042] 12-day-old Wistar suckling mice, male or female, weighing (20±5) g, were fed by female mice under normal conditions, and all mice were kept on a standard 12 / 12-hour day / night cycle, with free access to food and water.

[0043] 2. Modeling Drugs

[0044] NMDA (N-methyl-D-aspartate, N-methyl-D-Aspartate).

[0045] 3. Modeling method

[0046] Take 12-day-old Wistar suckling mice, and inject NMDA (N-methyl-D-aspartate, N-methyl-D-Aspartate) 15 mg / kg intraperitoneally every day at 8:30-10:00 in the morning for 14 consecutive days . The animals were continuously observed for 2 hours after each injection, and corresponding records were made on the incubation period, seizure type, incidence rate and behavior changes of the epileptic seizures. The modeling was considered successful if the following manifestations occurred: Automatisms such as t...

Embodiment 2

[0047] Example 2 Effect of cannabidiol and vigabatrin in synergistic treatment of West syndrome

[0048] 1. Experimental method

[0049] On the day of the experiment, 40 Wistar suckling mice treated according to the method of Example 1 were randomly divided into four groups, administered within 30 minutes after the seizure, and then observed the performance of the tested animals after the administration.

[0050] Control group: 0.9% normal saline;

[0051] Combination drug group 1: Cannabidiol (200mg / kg) and vigabatrin (100mg / kg) composition;

[0052] Combination group 2: Cannabidiol (200mg / kg) and vigabatrin (10mg / kg) composition;

[0053] Combination group 3: Cannabidiol (20mg / kg) and vigabatrin (100mg / kg) composition;

[0054] Combination group 4: Cannabidiol (50mg / kg) and vigabatrin (100mg / kg) composition;

[0055] Cannabidiol group 1: (200mg / kg);

[0056] Cannabidiol group 2: (20mg / kg);

[0057] Cannabidiol group 3: (50mg / kg);

[0058] Vigabatrin group 1: (100mg / kg...

Embodiment 3

[0065] Example 3 Cannabidiol combined with vigabatrin reduces diarrhea symptoms

[0066] Establish the West syndrome suckling mouse model according to the method of embodiment 1 and divide into 3 groups at random according to body weight, every group 10, concrete grouping method is:

[0067] The control group was given an equal volume of normal saline;

[0068] Combination drug group 1: Cannabidiol (200mg / kg) and vigabatrin (100mg / kg) composition;

[0069] Combination group 2: Cannabidiol (200mg / kg) and vigabatrin (10mg / kg) composition;

[0070] Combination group 3: Cannabidiol (20mg / kg) and vigabatrin (100mg / kg) composition;

[0071] Combination group 4: Cannabidiol (50mg / kg) and vigabatrin (100mg / kg) composition;

[0072] Cannabidiol group 1: (200mg / kg);

[0073] Cannabidiol group 2: (20mg / kg);

[0074] Cannabidiol group 3: (50mg / kg);

[0075] Vigabatrin group 1: (100mg / kg);

[0076] Vigabatrin group 2: (10mg / kg).

[0077]The above-mentioned groups were administered ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition and provides a method for treating West syndrome by using the composition and application of the composition in preparation of a medicine used for treating the West syndrome. The composition contains cannabidiol and vigabatrin and can comprise one or multiple medicinal carriers or excipients, wherein dosage of cannabidiol and dosage of vigabatrin enable the effect of the composition to be better than the effect when each medicine in the dosage is used alone.

Description

technical field [0001] The invention relates to a composition and its application in treating epilepsy, in particular to a composition of cannabidiol and vigabatrin and its application in treating West syndrome (infantile spasms). Background technique [0002] Epilepsy is a chronic brain disease caused by a variety of etiologies, characterized by recurrent, paroxysmal and transient central nervous system dysfunction caused by excessive discharge of brain neurons. A chronic brain disease state with recurrent episodes of underlying and multiple clinical manifestations rather than a single disease. Epilepsy occurs in people of any age, region and race, but the incidence is higher in children and adolescents. Among epilepsy patients, children account for about 2 / 3 of all epilepsy patients. [0003] In childhood epilepsy, West syndrome (also known as infantile spasms, nodding eclampsia, etc.) is a relatively special subtype, which was named after West's first report in 1841. We...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/197A61K31/05A61P25/08
CPCA61K31/05A61K31/197A61K2300/00
Inventor 张可谭昕常坦然金倩
Owner HANYI BIO TECH CO LTD